GD-11 for Injection in the Treatment of Acute Ischemic Stroke

Status Recruiting

Clinical Trial Summary

Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study with the primary objective of evaluation of the efficacy and safety of GD-11 for injection in the treatment of acute ischemic stroke patients within 48 hours. The subject has a clinical diagnosis of acute ischemic stroke, within 48 hours from stroke onset to start of study treatment, with a National Institutes of Health Stroke Scale (NIHSS) between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with mRS score ≤ 1 at 90 days after treatment.

Clinical Trial Description

A multicenter, randomized, double-blind, parallel, placebo-controlled trial design was used. Subjects were randomly assigned in a 1:1 ratio to the experimental group (GD-11 for injection treatment group) and the control group (GD-11 for injection placebo group). Randomization stratification factors included onset time (≤24 hours, >24 hours) and center.Continuous treatment was performed for 10 days (20 times), followed up to 90 days after the first administration. The trial was divided into three phases: screening/baseline phase, treatment phase, and follow-up phase. Screening/baseline phase: Subjects entered the screening/baseline phase after signing the informed consent for screening examinations. Treatment phase: Eligible subjects were randomly assigned in a 1:1 ratio to receive GD-11 for injection or placebo for injection for 10 days (20 times). During the treatment, protocol-required examinations were performed and safety was evaluated. Follow-up phase: Subjects who completed the treatment entered the follow-up phase and were followed up to 90 days after the first administration. Stroke-related scale scores were performed on the 10th, 30th, and 90th days after the first use of the test drug. Adverse events were recorded during the treatment and follow-up phases to further evaluate safety. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06299579
Study type	Interventional
Source	Beijing Tiantan Hospital
Contact	Yongjun Wang
Phone	+86 10 5997 8538
Email	yongjunwang111@aliyun.com
Status	Recruiting
Phase	Phase 3
Start date	February 29, 2024
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06113848` - Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy	Phase 3
Completed	`NCT04069546` - The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency	N/A
Active, not recruiting	`NCT05700097` - Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy	Phase 2
Recruiting	`NCT06058130` - Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis	N/A
Recruiting	`NCT04415164` - Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke	Phase 4
Recruiting	`NCT05363397` - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke	Phase 2
Completed	`NCT05429658` - Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System	N/A
Recruiting	`NCT05390580` - Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct	N/A
Enrolling by invitation	`NCT05515393` - A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke	Phase 2
Active, not recruiting	`NCT05070260` - ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo	Phase 2/Phase 3
Terminated	`NCT05547412` - Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
Completed	`NCT03366818` - New Stent Retriever, VERSI System for AIS	N/A
Not yet recruiting	`NCT06040476` - Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)	Phase 2
Not yet recruiting	`NCT05293080` - Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE	Phase 3
Not yet recruiting	`NCT06437431` - Glenzocimab in Anterior Stroke With Large Ischemic Core Eligible for Endovascular Therapy	Phase 2/Phase 3
Completed	`NCT02223273` - Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)	N/A
Completed	`NCT02586233` - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke	Phase 1/Phase 2
Not yet recruiting	`NCT01594190` - Physical Activity Immediately After Acute Cerebral Ischemia	N/A
Terminated	`NCT01694381` - Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor	Early Phase 1
Completed	`NCT01120301` - Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.